

1. PATIENT INITIALS (first, last) PRIVACY	1a. COUNTRY COSTA RICA	2. DATE OF BIRTH			2a. AGE 44 Years	3. SEX Female	3a. WEIGHT 83.00 kg	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION
		Day	Month	Year				Day	Month	Year	
7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data) Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas) she feels very stagnant.								2024			<input type="checkbox"/> PATIENT DIED <input type="checkbox"/> INVOLVED OR PROLONGED INPATIENT HOSPITALISATION <input type="checkbox"/> INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY <input type="checkbox"/> LIFE THREATENING <input type="checkbox"/> CONGENITAL ANOMALY <input type="checkbox"/> OTHER
(Continued on Additional Information Page)											

14. SUSPECT DRUG(S) (include generic name) #1) Saxenda (liraglutide 6 mg/mL) Solution for injection, 6 mg/mL <div style="text-align: right;">(Continued on Additional Information Page)</div>		20. DID REACTION ABATE AFTER STOPPING DRUG? <input type="checkbox"/> YES <input checked="" type="checkbox"/> NO <input type="checkbox"/> NA
15. DAILY DOSE(S) #1) 1.8 mg, qd (Continued on Additional Information Page)	16. ROUTE(S) OF ADMINISTRATION #1) Subcutaneous	21. DID REACTION REAPPEAR AFTER REINTRODUCTION? <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
17. INDICATION(S) FOR USE #1) For weight loss (Weight control)		
18. THERAPY DATES(from/to) #1) 2024 / Unknown	19. THERAPY DURATION #1) Unknown	

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)		
#1) METFORMIN (METFORMIN) ; 2022 / Ongoing		
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)		
From/To Dates	Type of History / Notes	Description
2022 to Ongoing	Current Condition	Metabolic syndrome (Metabolic syndrome)
	3 years ago	

24a. NAME AND ADDRESS OF MANUFACTURER Novo Nordisk A/S Lise Grimmeshave Vandtaarnsvej 114 Soeborg, DK-2860 DENMARK Phone: +45 44448888		26. REMARKS Medically Confirmed: No
	24b. MFR CONTROL NO. 1431117	25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.
24c. DATE RECEIVED BY MANUFACTURER 18-JUN-2025	24d. REPORT SOURCE <input checked="" type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE <input type="checkbox"/> HEALTH PROFESSIONAL <input type="checkbox"/> OTHER:	
DATE OF THIS REPORT 09-JUL-2025	25a. REPORT TYPE <input checked="" type="checkbox"/> INITIAL <input type="checkbox"/> FOLLOWUP:	

ADDITIONAL INFORMATION

7+13. DESCRIBE REACTION(S) continued

She has not lost weight and not lost any weight this year [Weight loss poor]
has not seen any results [Drug ineffective]

Case Description: ***This is an auto generated narrative***

Study ID: 828652-My Healthy Journey

Study description: Trial title: This is a 40 weeks digital patient support program with focus on exercise, motivation, nutrition & maintaining strategies (only for patients under Liraglutide 3.0 mg).

Patient's height: 164 cm.

Patient's weight: 83 kg.

Patient's BMI: 30.85960740.

This non-serious Solicited Report from COSTA RICA was reported by a Consumer as "she feels very stagnant. She has not lost weight and not lost any weight this year(Weight loss poor)" beginning on 2024 , "has not seen any results(Drug ineffective)" beginning on 2024 and concerned a 44 Years old Female patient who was treated with Saxenda (liraglutide 6 mg/mL) from 2024 for "For weight loss",

Dosage Regimens:
Saxenda: ??-???-2024 to Not Reported;

Current Condition: Metabolic syndrome.

Concomitant medications included - METFORMIN.

Batch Numbers:
Saxenda: ASKU;

Action taken to Saxenda was reported as Product discontinued due to AE.

The outcome for the event "she feels very stagnant. She has not lost weight and not lost any weight this year(Weight loss poor)" was Not recovered.
The outcome for the event "has not seen any results(Drug ineffective)" was Not recovered.

Reporter's causality (Saxenda) -
she feels very stagnant. She has not lost weight and not lost any weight this year(Weight loss poor) : Possible
has not seen any results(Drug ineffective) : Possible

Company's causality (Saxenda) -
she feels very stagnant. She has not lost weight and not lost any weight this year(Weight loss poor) : Possible
has not seen any results(Drug ineffective) : Possible

Reporter Comment: The doctor changed the medication.

14-19. SUSPECT DRUG(S) continued

14. SUSPECT DRUG(S) (include generic name)	15. DAILY DOSE(S); 16. ROUTE(S) OF ADMIN	17. INDICATION(S) FOR USE	18. THERAPY DATES (from/to); 19. THERAPY DURATION
#1) Saxenda (liraglutide 6 mg/mL) Solution for injection, 6 mg/mL; Regimen #1	1.8 mg, qd (Start date: Mid-year (2024)); Subcutaneous	For weight loss (Weight control)	2024 / Unknown; Unknown